GBT Announces Participation at the 2018 Cantor Global Healthcare Conference
September 26, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Cantor Global Healthcare...
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Alnylam, Global Blood, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm
September 24, 2018 19:19 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Alnylam Pharmaceuticals, Inc.,...
GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
August 23, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today that it has entered into an exclusive worldwide licensing agreement...
GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference
August 07, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Wedbush PacGrow Healthcare...
GBT Announces New Employment Inducement Grants
August 03, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on August 1, 2018, the compensation committee of the...
GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results
August 02, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the second quarter ended...
GBT Announces New Employment Inducement Grants
July 03, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that, on July 2, 2018, the compensation committee of the Company’s...
GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
June 27, 2018 07:30 ET
|
Global Blood Therapeutics, Inc.
Primary Endpoint Achieved; 58 Percent of Patients on Voxelotor Dosed with 1500 mg at Week 12 Exceeded 1 g/dL Increase in Hemoglobin Versus 9 Percent of Placebo (p<0.0001) Company Met with FDA on...
GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress
June 15, 2018 02:30 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new 24-week data from patients treated with the 900 mg dose of...
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Research’s 12th Annual Symposium
June 08, 2018 08:30 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts related to the voxelotor program in sickle cell...